Adalimumab
- Generic Name
- Adalimumab
- Brand Names
- Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 331731-18-1
- Unique Ingredient Identifier
- FYS6T7F842
- Background
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...
- Indication
Adalimumab is indicated for the following conditions:
Adalimumab has also been used off-label to treat Pyoderma gangrenosum.
- Associated Conditions
- Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum
- Associated Therapies
- -
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
- Conditions
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 400
- Registration Number
- NCT03414502
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 478
- Registration Number
- NCT03412747
- Locations
- 🇺🇸
Ps0008 905, Overland Park, Kansas, United States
🇨🇳Ps0008 755, Taipei, Taiwan
🇭🇺Ps0008 260, Szeged, Hungary
Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Shanghai Henlius Biotech
- Target Recruit Count
- 220
- Registration Number
- NCT03357939
- Locations
- 🇨🇳
the 1st affiliated hospital of Jilin University, Chang Chun, Jilin, China
Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Shanghai Henlius Biotech
- Target Recruit Count
- 262
- Registration Number
- NCT03316781
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 22
- Registration Number
- NCT03311464
- Locations
- 🇯🇵
Nagoya City University Hospital /ID# 164510, Nagoya-shi, Aichi, Japan
🇯🇵Juntendo University Urayasu Hospital /ID# 164422, Urayasu Shi, Chiba, Japan
🇯🇵Fukuoka University Hospital /ID# 164416, Fukuoka-shi, Fukuoka, Japan
A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects
- First Posted Date
- 2017-09-06
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 74
- Registration Number
- NCT03273192
- Locations
- 🇮🇷
Orchidpharmed PK/PD site, Tehran, Iran, Islamic Republic of
A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.
- Conditions
- Interventions
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 90
- Registration Number
- NCT03248531
- Locations
- 🇺🇸
Hs0001 115, Las Vegas, Nevada, United States
🇧🇪Hs0001 203, Brussels, Belgium
🇳🇴Hs0001 701, Harstad, Norway
Repurposing Anti-TNF for Treating Dupuytren's Disease
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 140
- Registration Number
- NCT03180957
- Locations
- 🇬🇧
NHS Lothian, Edinburgh, United Kingdom
🇬🇧Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
🇳🇱The University Medical Centre, Groningen, Netherlands
Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA
- Conditions
- Interventions
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 136
- Registration Number
- NCT03172325
- Locations
- 🇮🇷
Alzahra Hospital, Isfahan, Iran, Islamic Republic of
🇮🇷Imam Reza Hospital (501 Artesh), Tehran, Iran, Islamic Republic of
🇮🇷Noor Medical Complex, Tabriz, Iran, Islamic Republic of
A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 566
- Registration Number
- NCT03151551
- Locations
- 🇮🇳
Sir Ganga Ram Hospital, New Delhi, Delhi, India
🇧🇪Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium
🇮🇳Krishna Institute of Medical Sciences Ltd., Secunderabad, Telengana, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.